Shenzhen Salubris Pharmaceuticals Co., Ltd. (SHE:002294)
China · Delayed Price · Currency is CNY 30.93
+0.78 (2.59%)
Oct 9, 2026, 3:04 PM CST
SHE:002294 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 8, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 34,279 | 55,239 | 34,481 | 35,644 | 36,225 | 30,220 | |
Market Cap Growth | -49.05% | 60.20% | -3.26% | -1.60% | 19.87% | 3.71% |
Enterprise Value | 32,524 | 53,220 | 32,688 | 33,898 | 33,154 | 27,017 |
Last Close Price | 30.93 | 48.77 | 30.05 | 31.16 | 30.91 | 25.23 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 8, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | 51.58 | 84.79 | 57.32 | 61.45 | 56.86 | 56.62 |
Forward PE | - | 75.65 | 51.55 | 58.32 | 54.75 | 27.88 |
PS Ratio | 7.29 | 12.69 | 8.59 | 10.59 | 10.40 | 9.88 |
PB Ratio | 3.94 | 6.10 | 3.94 | 4.43 | 4.54 | 3.76 |
P/TBV Ratio | 4.94 | 7.56 | 4.68 | 5.33 | 5.24 | 4.38 |
P/FCF Ratio | 399.91 | 705.15 | 61.42 | 211.61 | 97.42 | 43.02 |
P/OCF Ratio | 31.35 | 52.49 | 29.07 | 42.46 | 37.32 | 25.50 |
PEG Ratio | - | 1.15 | 1.15 | 1.15 | 1.15 | 1.15 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 8, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 6.92 | 12.23 | 8.15 | 10.07 | 9.52 | 8.83 |
EV/EBITDA Ratio | 30.64 | 51.73 | 31.24 | 37.95 | 37.95 | 33.84 |
EV/EBIT Ratio | 49.48 | 83.10 | 47.80 | 59.91 | 58.62 | 53.57 |
EV/FCF Ratio | 379.43 | 679.37 | 58.22 | 201.24 | 89.16 | 38.46 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 8, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 0.05 | 0.03 | 0.02 | 0.01 | 0.03 | 0.01 |
Debt / EBITDA Ratio | 0.40 | 0.28 | 0.13 | 0.07 | 0.24 | 0.10 |
Debt / FCF Ratio | 5.00 | 3.70 | 0.24 | 0.38 | 0.56 | 0.11 |
Net Debt / Equity Ratio | -0.22 | -0.31 | -0.31 | -0.27 | -0.42 | -0.40 |
Net Debt / EBITDA Ratio | -1.78 | -2.72 | -2.59 | -2.40 | -3.80 | -4.03 |
Net Debt / FCF Ratio | -21.93 | -35.75 | -4.83 | -12.70 | -8.93 | -4.58 |
Asset Turnover | 0.43 | 0.40 | 0.40 | 0.35 | 0.37 | 0.38 |
Inventory Turnover | 2.19 | 2.10 | 2.28 | 2.06 | 2.08 | 2.00 |
Quick Ratio | 1.68 | 1.97 | 3.09 | 3.40 | 2.56 | 3.88 |
Current Ratio | 2.03 | 2.28 | 3.62 | 4.07 | 2.94 | 4.35 |
Return on Equity (ROE) | 7.68% | 7.33% | 7.20% | 7.25% | 7.92% | 7.75% |
Return on Assets (ROA) | 3.79% | 3.68% | 4.30% | 3.69% | 3.72% | 3.90% |
Return on Invested Capital (ROIC) | 9.29% | 10.37% | 10.95% | 9.69% | 10.60% | 9.13% |
Return on Capital Employed (ROCE) | 7.20% | 6.90% | 7.30% | 6.60% | 6.90% | 6.10% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 8, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | 1.96% | 1.18% | 1.75% | 1.63% | 1.76% | 1.77% |
FCF Yield | 0.25% | 0.14% | 1.63% | 0.47% | 1.03% | 2.33% |
Dividend Yield | 1.78% | 1.13% | 1.66% | 1.60% | 1.62% | 1.59% |
Payout Ratio | 91.46% | 85.68% | 90.77% | 94.71% | 69.25% | 2.91% |
Buyback Yield / Dilution | -0.98% | -0.83% | 0.13% | -1.55% | -2.90% | -5.23% |
Total Shareholder Return | 0.79% | 0.30% | 1.80% | 0.05% | -1.28% | -3.64% |